Drug-Resistant “Superbug Fungus” Intensifies Global Healthcare Threat

A deadly, drug-resistant fungus rapidly spreading through hospitals across the United States is becoming an even more formidable threat worldwide, according to a comprehensive scientific review published in early December.

Candida auris (C. auris), commonly described as a “superbug fungus,” is increasingly resisting human immune systems while expanding its global footprint, warn researchers from the Hackensack Meridian Center for Discovery and Innovation (CDI).

The findings reinforce previous CDC warnings that have designated C. auris as an “urgent antimicrobial threat” — the first fungal pathogen to receive such a serious classification. Approximately 7,000 cases were identified across dozens of U.S. states in 2025, according to CDC data, with the pathogen now detected in at least 60 countries worldwide.

First identified in 2009 from a patient’s ear sample in Japan, C. auris has since spread internationally, causing outbreaks severe enough to force some hospital intensive care units to temporarily shut down operations. The fungus poses the greatest danger to critically ill patients, particularly those on ventilators or with compromised immune systems. Once infected, mortality rates reach approximately 50% in some studies.

“It is resistant to multiple antifungal drugs, and it tends to spread in hospital settings, including on equipment being used on immunocompromised and semi-immunocompromised patients, such as ventilators and catheters,” explained Dr. Marc Siegel, Fox News senior medical analyst and clinical professor of medicine at NYU Langone.

The comprehensive review was conducted by Dr. Neeraj Chauhan of the Hackensack Meridian CDI, Dr. Anuradha Chowdhary from the University of Delhi’s Medical Mycology Unit, and Dr. Michail Lionakis, who heads the clinical mycology program at the National Institutes of Health. Their findings, published in Microbiology and Molecular Biology Reviews, highlight why the pathogen proves so difficult to contain.

Unlike many other fungi, C. auris demonstrates unusual resilience, able to survive on human skin and adhere to hospital surfaces and medical equipment. This characteristic allows it to spread efficiently in healthcare settings, creating persistent contamination that challenges standard cleaning protocols.

The researchers stress that current diagnostic capabilities and treatment options have not kept pace with the pathogen’s evolution. Their review emphasizes the urgent need to develop “novel antifungal agents with broad-spectrum activity against human fungal pathogens, to improve diagnostic tests, and to develop immune- and vaccine-based adjunct modalities for the treatment of high-risk patients.”

Another significant challenge is the frequent misdiagnosis of C. auris infections, as its symptoms — including fever, chills and aches — mimic those of many other conditions. This diagnostic confusion often delays proper treatment and implementation of necessary infection control measures.

Currently, healthcare providers have only four major classes of antifungal drugs at their disposal, and C. auris has already demonstrated resistance to many of them. While three new antifungal medications have been approved or are in late-stage clinical trials, researchers warn that drug development struggles to match the rapid adaptation of the fungus.

Despite these concerning trends, recent scientific breakthroughs offer some hope. In separate research published in December, scientists at the University of Exeter in England identified a potential vulnerability in C. auris while studying the fungus in a living-host model.

The Exeter team discovered that during infection, C. auris activates specific genes to scavenge iron — a nutrient essential for its survival. This finding, published in the journal Communications Biology, suggests that medications targeting this iron acquisition pathway could potentially halt infections or allow for repurposing existing drugs.

“We think our research may have revealed an Achilles’ heel in this lethal pathogen during active infection,” said Dr. Hugh Gifford, a clinical lecturer at the University of Exeter and study co-author.

Public health officials emphasize that while C. auris presents a serious concern for healthcare facilities and vulnerable patients, it does not typically threaten healthy individuals. The primary focus remains on developing better surveillance, implementing rigorous infection control measures, accelerating diagnostic capabilities, and investing in new treatment approaches.

As researchers race to better understand this evolving threat, healthcare systems worldwide face mounting pressure to balance patient care with containment strategies for this increasingly resistant fungal pathogen.